Regeneron (REGN) Gains But Lags Market: What You Should Know

·3 min read

Regeneron (REGN) closed at $759.76 in the latest trading session, marking a +0.07% move from the prior day. The stock lagged the S&P 500's daily gain of 1.3%. Meanwhile, the Dow gained 0.98%, and the Nasdaq, a tech-heavy index, added 7.48%.

Coming into today, shares of the biopharmaceutical company had gained 1.4% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 2.95%.

Regeneron will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $9.54, down 16.97% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.94 billion, down 0.93% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $41 per share and revenue of $12.48 billion, which would represent changes of -8.85% and +2.54%, respectively, from the prior year.

Any recent changes to analyst estimates for Regeneron should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Regeneron is currently sporting a Zacks Rank of #3 (Hold).

Digging into valuation, Regeneron currently has a Forward P/E ratio of 18.52. For comparison, its industry has an average Forward P/E of 18.52, which means Regeneron is trading at a no noticeable deviation to the group.

Also, we should mention that REGN has a PEG ratio of 2.18. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.67 based on yesterday's closing prices.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 92, putting it in the top 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research